A pilot clinical trial to determine the potentials of a 3-day, 200 mg 6 hourly course of Rifaximin by comparing its efficacy with that of a 3-day, 500 mg 12 hourly dose of ciprofloxacin in the treatment of adults with clinically severe cholera due to V. cholerae O1 or O139